In a major leap forward for cancer diagnostics and treatment, Mumbai’s Kokilaben Dhirubhai Ambani Hospital has launched OncoKH 500 PLUS, a comprehensive next-generation genomic profiling platform capable of analyzing over 500 cancer-related genes in a single test. This makes it the first hospital in Mumbai to offer a complete in-house precision oncology solution—from genetic testing to individualized treatment—all under one roof.
The OncoKH 500 PLUS platform is designed to detect a wide range of genomic alterations including single nucleotide variants (SNVs), gene fusions, copy number variations (CNVs), tumor mutational burden (TMB), microsatellite instability (MSI), and homologous recombination deficiency (HRD). These insights empower oncologists to make faster, more targeted treatment decisions, particularly for patients with advanced or metastatic cancers.
Dr. Santosh Shetty, Executive Director & CEO of Kokilaben Hospital, remarked,
“We’ve developed an oncology ecosystem that reflects the highest global standards. OncoKH 500 PLUS represents a significant advancement in precision oncology, giving patients in India access to transformative genetic insights that guide personalised cancer care.”
Unlike conventional approaches that often require samples to be sent abroad, this test is performed entirely in-house, significantly reducing turnaround time and easing patient stress. A single biopsy provides a complete and accurate genetic report, enabling quicker initiation of personalised treatments such as targeted therapy or immunotherapy.
Dr. Amrit Kaur Kaler, Consultant in Molecular Pathology, highlighted,
“Cancers don’t behave uniformly, and many patients are resistant to standard chemotherapy due to underlying mutations. This platform lets us map the full genetic landscape of a tumor, from actionable mutations to resistance markers, helping us tailor treatment from day one. Even within the first month, we’ve seen highly promising responses from both Indian and international patients.”
Comprehensive gene profiling: Covers over 500 cancer-associated genes, detecting SNVs, indels, fusions, CNVs, TMB, MSI, and HRD
Fully in-house testing: Ensures fast turnaround, data confidentiality, and lower anxiety for patients
Aligned with international standards: Follows NCCN guidelines and biomarker-driven treatment protocols
Supports personalised therapies: Helps guide first-line treatment, targeted therapy, immunotherapy, and clinical trial matching
Expert integration: Backed by molecular tumor boards and specialist-led genetic counselling
With this launch, Kokilaben Hospital aims to redefine the standard of cancer care in India—making world-class, genetics-driven oncology more accessible and efficient.